Q1 Earnings Forecast for Immunic Issued By William Blair

Immunic, Inc. (NASDAQ:IMUX) – Stock analysts at William Blair issued their Q1 2025 earnings estimates for Immunic in a research report issued on Wednesday, April 30th. William Blair analyst M. Minter forecasts that the company will post earnings of ($0.25) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic’s Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $1.05 EPS.

A number of other brokerages also recently commented on IMUX. B. Riley restated a “buy” rating and issued a $6.00 target price on shares of Immunic in a research note on Wednesday, April 16th. D. Boral Capital reissued a “buy” rating and issued a $17.00 price target on shares of Immunic in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday. Finally, StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Immunic has a consensus rating of “Buy” and a consensus target price of $13.20.

Immunic Stock Down 1.7 %

Immunic stock opened at $1.15 on Friday. Immunic has a 12 month low of $0.83 and a 12 month high of $2.11. The stock has a market cap of $110.19 million, a P/E ratio of -0.93 and a beta of 1.91. The company’s fifty day simple moving average is $1.08 and its 200-day simple moving average is $1.11.

Institutional Investors Weigh In On Immunic

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. acquired a new position in Immunic during the fourth quarter valued at approximately $37,000. Virtu Financial LLC bought a new stake in shares of Immunic during the 3rd quarter worth $50,000. HB Wealth Management LLC acquired a new position in Immunic in the 4th quarter valued at $81,000. Barclays PLC bought a new position in Immunic in the 4th quarter worth $84,000. Finally, Jane Street Group LLC lifted its position in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.